Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Invivac vs Influvac vs Fluad in elderly – immunogenicity comparison
2004-002225-45Phase 3Completed
- Sponsor
- Solvay Pharmaceuticals
- Start
- Oct 2004
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of virosomal influenza vaccine in influenza (3 arms), sponsored by Solvay Pharmaceuticals. Primary endpoint: Hemagglutination inhibition (HI) antibody titers. Started Oct 2004; status: completed.
02
Drugs
virosomal influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2004-002225-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002225-45.